Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for monomorphic epitheliotropic intestinal T-cell lymphoma has been reported in the published literature.
5 clinical trials registered, 2 recruiting. Interventions under study include drug therapy, biologic therapy, and other interventions. Pipeline includes 4 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT03598998](https://clinicaltrials.gov/study/NCT03598998) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 10:58 PM UTC
European rare disease database
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
PHASE1 |
City of Hope Medical Center |
ACTIVE_NOT_RECRUITING |
[NCT05978141](https://clinicaltrials.gov/study/NCT05978141) | A Registry for People With T-cell Lymphoma | — | Memorial Sloan Kettering Cancer Center | RECRUITING |
[NCT05377827](https://clinicaltrials.gov/study/NCT05377827) | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies | PHASE1 | Washington University School of Medicine | UNKNOWN |
[NCT05475925](https://clinicaltrials.gov/study/NCT05475925) | A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas | PHASE1 | Dren Bio | RECRUITING |
[NCT07388563](https://clinicaltrials.gov/study/NCT07388563) | Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma | PHASE1 | National Cancer Institute (NCI) | UNKNOWN |
41 publications have been identified in PubMed for monomorphic epitheliotropic intestinal T-cell lymphoma. Research spans Case Report / Case Series (61%), Review / Meta-Analysis (15%), and Diagnostic / Biomarker (10%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 25 | 61% |
Research summaries | 6 | 15% |
Testing and diagnosis research | 4 | 10% |
Disease patterns and progression | 2 | 5% |
Other research | 1 | 2% |
Clinical study results | 1 | 2% |
Laboratory research | 1 | 2% |
New treatment approaches | 1 | 2% |
Xu X (2026). [PMID: 41788996](https://pubmed.ncbi.nlm.nih.gov/41788996/). *Front Oncol*. [Case Report / Case Series]
Zhao TQ (2026). [PMID: 42184067](https://pubmed.ncbi.nlm.nih.gov/42184067/). *Indian J Gastroenterol*. [Case Report / Case Series]
She YF (2026). [PMID: 42085090](https://pubmed.ncbi.nlm.nih.gov/42085090/). *Niger J Clin Pract*. [Case Report / Case Series]
Xue S (2026). [PMID: 41727656](https://pubmed.ncbi.nlm.nih.gov/41727656/). *Front Oncol*. [Case Report / Case Series]
Vallois D (2026). [PMID: 41057685](https://pubmed.ncbi.nlm.nih.gov/41057685/). *Leukemia*. [Basic Science / Preclinical]
Ichikawa T (2026). [PMID: 41328359](https://pubmed.ncbi.nlm.nih.gov/41328359/). *Radiol Case Rep*. [Case Report / Case Series]
Boughanmi F (2026). [PMID: 42057140](https://pubmed.ncbi.nlm.nih.gov/42057140/). *J Med Case Rep*. [Case Report / Case Series]
Cheo FF (2026). [PMID: 42011981](https://pubmed.ncbi.nlm.nih.gov/42011981/). *J Cutan Pathol*. [Case Report / Case Series]
Chuang MP (2026). [PMID: 40908410](https://pubmed.ncbi.nlm.nih.gov/40908410/). *Dig Dis Sci*. [Diagnostic / Biomarker]
Yeh WC (2026). [PMID: 41578186](https://pubmed.ncbi.nlm.nih.gov/41578186/). *BMC Gastroenterol*. [Case Report / Case Series]